New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 17, 2012
09:25 EDTEDAP, EDAPEDAP TMS to host special shareholder meeting
Special shareholder meeting to be held in France on December 19 at 4:30 pm.
News For EDAP From The Last 14 Days
Check below for free stories on EDAP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 31, 2014
12:29 EDTEDAPOn The Fly: Midday Wrap
Subscribe for More Information
07:12 EDTEDAPEDAP TMS price target lowered to $4.50 from $6 at H.C. Wainwright
H.C. Wainwright lowered its price target for EDAP TMS shares to $4.50 saying a positive FDA decision is unlikely after an FDA panel was "unanimously negative" on the company's treatment of low-risk, localized prostate cancer. The firm still believes Ablatherm will continue to grow its market share in Europe and keeps a Buy rating on the stock.
07:10 EDTEDAPEDAP TMS says FDA panel votes against Ablatherm-HIFU device
EDAP TMS announced last night that the FDA's Gastroenterology and Urology Devices Panel voted 3 yes, 5 no with 1 abstention on the question of safety, 9 no on the question of efficacy, and 8 no with 1 abstention for the risk/benefit ratio for the use of its Ablatherm-HIFU device for the treatment of low-risk, localized prostate cancer. Marc Oczachowski, EDAP's CEO, commented, "We are disappointed by the Committee's recommendation regarding Ablatherm-HIFU for the treatment of low-risk, localized prostate cancer and we appreciate the dialogue during today's meeting. We look forward to subsequent discussion with the FDA. We will continue to work diligently with the FDA as it carefully completes its final review for Ablatherm-HIFU's PMA."
July 30, 2014
14:34 EDTEDAPEDAP TMS halted, news pending
Subscribe for More Information
07:31 EDTEDAPFDA Gastroenterology and Urology Devices Panel to hold a meeting
Subscribe for More Information
July 28, 2014
15:12 EDTEDAPEDAP TMS downgraded to Market Perform from Outperform at Northland
Subscribe for More Information
14:09 EDTEDAPEDAP TMS volatility elevated into FDA meeting
EDAP TMS August option implied volatility is at 228, September is at 151, November is at 106; compared to its 26-week average of 109 according to Track Data, suggesting large price movement into an expected FDA--CDRH - gastroenterology and urology devices panel meeting on June 30.
July 18, 2014
14:08 EDTEDAPEDAP TMS volatility elevated into FDA meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use